Global Apheresis Market Overview:
Apheresis is a medical technology in which the blood of a person is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation. The increasing demand for blood components and growing concerns regarding blood safety across the globe, rising prevalence of various blood disorders, increasing number of surgical procedures and emergency care cases in hospitals around the world are driving market growth. Extending reach of apheresis in the untapped paediatric segment and growth in emerging markets due to increasing investments presents significant growth opportunities for players in this market. However, high costs of apheresis machines & procedures and scarcity of qualified donors are the major restraining factors for this market.
- Rising Prevalence of Chronic Diseases and Growing Number of Trauma and Injury Cases
- Rising Demand for Blood Components and Growing Concerns Regarding Blood Safety
- Increase in the Number of Complex Surgical Procedures
- Increasing Demand for Source Plasma From Biopharmaceutical Companies
- Favourable Reimbursement for Apheresis Procedures
- High Cost of Apheresis Devices & Therapeutic Apheresis Procedures and Installation of Apheresis Devices Through Rental Model
- Fewer Blood Donations Using Apheresis Due to Lack of Awareness
- Stringent Donor Recruitment Criteria
- Apheresis for Leukemia and Pediatric Patients
- Emerging Economies With Increasing Investments From Government Bodies and Leading Players
- Recruitment of Voluntary Non-Remunerated Donors
- Safety of Blood Transfusion in Developing Countries
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Terumo BCT, Inc. (United States), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (United States), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (United States), Cerus Corporation (United States), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan) and Nikkiso Co., Ltd. (Japan). Analyst at AMA Research see United States and Japanese Players to retain maximum share of Global Apheresis market by 2026. Considering Market by Technology, the sub-segment i.e. Centrifugation will boost the Apheresis market. Considering Market by Procedure, the sub-segment i.e. Automated blood collection (Donor Apheresis) will boost the Apheresis market.
Latest Market Insights:
In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Apheresis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Apheresis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Apheresis Procedure Giver, Apheresis Treatment Providers, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.